Literature DB >> 17325046

A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice.

Audrey Tanghe1, Pierre-Yves Adnet, Tatiana Gartner, Kris Huygen.   

Abstract

Buruli ulcer, caused by Mycobacterium ulcerans, is a necrotizing skin disease emerging particularly in West Africa. M. bovis BCG vaccine offers only short-term protection against experimental footpad infection of C57BL/6 mice with M. ulcerans, and the duration of this protection cannot be prolonged by a booster vaccination.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17325046      PMCID： PMC1865750          DOI： 10.1128/IAI.01622-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  17 in total

Review 1.  Vaccination against leprosy--the view from 1996.

Authors:  P E Fine; P G Smith
Journal:  Lepr Rev       Date:  1996-12       Impact factor: 0.537

2.  Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence.

Authors:  K M George; D Chatterjee; G Gunawardana; D Welty; J Hayman; R Lee; P L Small
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

3.  Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer).

Authors:  F Portaels; J Aguiar; M Debacker; C Steunou; C Zinsou; A Guédénon; W M Meyers
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

4.  Inhibition of multiplication of Mycobacterium leprae in mouse foot pads by recombinant Bacillus Catmette-Guérin (BCG).

Authors:  N Ohara; M Matsuoka; H Nomaguchi; M Naito; T Yamada
Journal:  Vaccine       Date:  2000-01-31       Impact factor: 3.641

5.  Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer.

Authors:  A Tanghe; J Content; J P Van Vooren; F Portaels; K Huygen
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

6.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

Authors:  Helen McShane; Ansar A Pathan; Clare R Sander; Sheila M Keating; Sarah C Gilbert; Kris Huygen; Helen A Fletcher; Adrian V S Hill
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

7.  Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.

Authors:  Jun Wang; Lisa Thorson; Richard W Stokes; Michael Santosuosso; Kris Huygen; Anna Zganiacz; Mary Hitt; Zhou Xing
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

8.  Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease.

Authors:  F Portaels; J Aguiar; M Debacker; A Guédénon; C Steunou; C Zinsou; W M Meyers
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  BCG vaccination against mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda.

Authors: 
Journal:  Lancet       Date:  1969-01-18       Impact factor: 79.321

Review 10.  Prospects for vaccine development against Buruli disease.

Authors:  Kris Huygen
Journal:  Expert Rev Vaccines       Date:  2003-08       Impact factor: 5.217
View more
  17 in total

Review 1.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

2.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

Review 3.  Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.

Authors:  Dezemon Zingue; Amar Bouam; Roger B D Tian; Michel Drancourt
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

4.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

5.  In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model.

Authors:  Till F Omansen; Renee A Marcsisin; Brendon Y Chua; Weiguang Zeng; David C Jackson; Jessica L Porter; Ymkje Stienstra; Tjip S van der Werf; Timothy P Stinear
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

Review 6.  Buruli ulcer disease: prospects for a vaccine.

Authors:  Kris Huygen; Ohene Adjei; Dissou Affolabi; Gisela Bretzel; Caroline Demangel; Bernhard Fleischer; Roch Christian Johnson; Jorge Pedrosa; Delphin M Phanzu; Richard O Phillips; Gerd Pluschke; Vera Siegmund; Mahavir Singh; Tjip S van der Werf; Mark Wansbrough-Jones; Françoise Portaels
Journal:  Med Microbiol Immunol       Date:  2009-02-07       Impact factor: 3.402

7.  BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.

Authors:  Paul J Converse; Deepak V Almeida; Eric L Nuermberger; Jacques H Grosset
Journal:  PLoS Negl Trop Dis       Date:  2011-03-15

8.  Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.

Authors:  Alexandra G Fraga; Teresa G Martins; Egídio Torrado; Kris Huygen; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

9.  Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.

Authors:  Bryan E Hart; Laura P Hale; Sunhee Lee
Journal:  PLoS Negl Trop Dis       Date:  2015-09-22

10.  Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting.

Authors:  Audrey Tanghe; Jean-Pierre Dangy; Gerd Pluschke; Kris Huygen
Journal:  PLoS Negl Trop Dis       Date:  2008-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.